Emergence and spread of VIM-type metallo-β-lactamase-producing Pseudomonas aeruginosa clinical isolates in Japan
Emergence and spread of VIM-type metallo-β-lactamase-producing Pseudomonas aeruginosa clinical isolates in Japan
复制标题
DOI：
10.1016/j.jgar.2020.09.010
复制
发表时间：
2020-12-01
影响因子：
4.6
通讯作者：
Kirikae, Teruo
中科院分区：
文献类型：
--
作者：
Hishinuma, Tomomi;Uchida, Hiroki;Kirikae, Teruo
目的：本研究的目的是确定产VIM型金属-β-内酰胺酶铜绿假单胞菌菌株的遗传和流行病学特性，这些菌株分离自日本患者。方法：从2012年至2018年在日本住院的患者中共获得1860株碳青霉烯类耐药铜绿假单胞菌临床分离株。通过PCR筛选碳青霉烯类耐药铜绿假单胞菌分离株的bla（Vim）基因。采用微量肉汤稀释法测定细菌对抗菌药物的敏感性。使用下一代测序仪对这些分离株的全基因组进行测序，并使用单核苷酸多态性串联体进行系统发育分析。多位点序列分型（MLST）和耐药基因进行了鉴定，使用全基因组序列data.Results：1860株，25个布拉病毒阳性菌株在日本的9个医疗机构进行了筛选。产VIM铜绿假单胞菌的数量在2012年至2018年期间显著增加。所有25株Blavim阳性菌株均对亚胺培南、美罗培南和环丙沙星耐药，但对粘菌素敏感。分离株携带bla（Vim-1）、blav（Vim-1）、bla（Vim-24）、bla（Vim-60）或新变体bla（Vim-66），并且属于四种不同的序列类型（ST），包括ST 179、ST 233、ST 235和ST 1816。携带bla（Vim-24）、bla（Vim-60）或bla（Vim-66）的11株分离株均来自同一家医院，均属于ST 1816。与Vim-2相比，Vim-24、Vim-60和Vim-66具有Arg 228 Leu的氨基酸替换。结论：在日本的医疗环境中，产生VIM型MBL的铜绿假单胞菌的数量有所增加。铜绿假单胞菌ST 1816产生Vim酶与Arg 228 Leu取代已经出现，并在日本的医疗环境中发展。(C)2020作者（S）由Elsevier Ltd代表国际抗微生物化疗学会发表。
Objectives: The aim of this study was to determine the genetic and epidemiological properties of Pseudomonas aeruginosa strains producing VIM-type metallo-p-lactamases isolated from patients in Japan.Methods: Atotal of 1860 clinical isolates of carbapenem-resistant P. aeruginosa were obtained from patients hospitalised in Japan from 2012-2018. Carbapenem-resistant P. aeruginosa isolates were screened for bla(VIM) genes by PCR. Antimicrobial susceptibility was determined by the broth microdilution method. The whole genomes of these isolates were sequenced using a next-generation sequencer, and phylogenetic analysis was performed using single nucleotide polymorphism concatemers. Multilocus sequence typing (MLST) was performed and drug resistance genes were identified using whole-genome sequence data.Results: Of 1860 isolates, 25 blavim-positive isolates were screened in nine medical settings in Japan. The population of VIM-producing P. aeruginosa significantly increased between 2012 and 2018. All 25 blavimpositive isolates were resistant to imipenem, meropenem and ciprofloxacin but were susceptible to colistin. The isolates harboured bla(VIM-1), blav(VIM-1), bla(VIM-24), bla(VIM-60) or the novel variant bla(VIM-66) and belonged to four different sequence types (STs), including ST179, ST233, ST235 and ST1816. The 11 isolates harbouring bla(VIM-24), bla(VIM-60) or bla(VIM-66) were obtained from a single hospital, all belonging to ST1816. VIM-24, VIM-60 and VIM-66 had an amino acid substitution (Arg228Leu) compared with VIM-2.Conclusions: The number of P. aeruginosa strains producing VIM-type MBLs has increased in medical settings in Japan. Pseudomonas aeruginosa ST1816 producing VIM enzymes with Arg228Leu substitution have emerged and evolved in a medical setting in Japan. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.